



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, C07K 14/47, 14/705, C12N 9/16, 9/64, A61K 38/17, 38/46, 38/47, C12N 15/55, 15/57, 5/08	A1	(11) International Publication Number: WO 00/06723 (43) International Publication Date: 10 February 2000 (10.02.00)
(21) International Application Number: PCT/IL99/00417 (22) International Filing Date: 29 July 1999 (29.07.99) (30) Priority Data: 125608 30 July 1998 (30.07.98) IL (71) Applicants (for all designated States except US): YEDA RESEARCH AND DEVELOPMENT COMPANY LTD AT THE WEIZMANN INSTITUTE OF SCIENCE [IL/IL]; P.O. Box 95, 76100 Rehovot (IL). BIO-TECHNOLOGY GENERAL CORP. [US/US]; 70 Wood Avenue South, Iselin, NJ 08830 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): EISENBACH, Lea. [IL/IL]; 33 Hanasi Harishon Street, 76303 Rehovot (IL). CARMON, Lior. [IL/IL]; 6 Kehilat Kiyov Street, 69989 Tel Aviv (IL). TIROSH, Boaz. [IL/IL]; 9 Stern Street, 55602 Kiryat Ono (IL). BAR-HAIM, Erez. [IL/IL]; 25/8 Hatsivony Street, 81573 Yavne (IL). PAZ, Adrian. [IL/IL]; 25 Wolfson Street, 49541 Petach Tikva (IL). FRIDKIN, Matityahu. [IL/IL]; 23 Miller Street, 76284 Rehovot (IL). FITZER-ATTAS, Cheryl. [US/IL]; 9 Sapir Street, 76227 Rehovot (IL).	(74) Agents: SCHUZ, David et al.; Bio-Technology General (Israel) Ltd., Patent Dept., Kiryat Weizmann, 76326 Rehovot (IL). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: TUMOR ASSOCIATED ANTIGEN PEPTIDES AND USE OF SAME AS ANTI-TUMOR VACCINES		
(57) Abstract The present invention relates to tumor associated antigen (TAA) peptides and to the use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.		

ABSTRACT

The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.